| Attributes | Values |
|---|
| rdf:type
| |
| rdfs:seeAlso
| |
| Description
| - The overall objective of this project is to develop new tools that would enable us to find new prognostic markers for childhood leukemia. This effort is in line with a long term goal to reveal new markers relevant for prediction of treatment failure in childhood leukemia. If such markers are found and verified on large cohort, the chemotherapeutic protocols can be adjusted for each patient to correspond with patient's risk of relapse (treatment failure) and in the same time patients can be saved from unnecessary therapy (and its adverse effects) if their risk of relapse is low. Treatment of childhood leukemia is currently achieved by using %22protocol treatment%22 that usually lasts at least 1.5 years and has elaborate sequence of therapeutical modalities that are combined in well controlled international studies. The Czech Republic is a member of the BFM-group (whose members also include Germany-Austria-Italy). This group develops leukemia treatment protocols that are the most successful in current pediatric hematology. Furthermore, several compounds were implemented in the recent years that act as %22targeted therapeutics%22 and target specifically the leukemia associated molecular abnormalities. The best example is imatinib mesylate (glivec) used for leukemias bearing the BCR/ABL translocation and many others small inhibitors. Our current task is to find appropriate role of these new compound in the treatment protocols and to find correlates of good response to these compounds. Large scale protein analysis, such as the antibody array technology is instrumental in finding the profile of good response of the leukemia cells.
- The overall objective of this project is to develop new tools that would enable us to find new prognostic markers for childhood leukemia. This effort is in line with a long term goal to reveal new markers relevant for prediction of treatment failure in childhood leukemia. If such markers are found and verified on large cohort, the chemotherapeutic protocols can be adjusted for each patient to correspond with patient's risk of relapse (treatment failure) and in the same time patients can be saved from unnecessary therapy (and its adverse effects) if their risk of relapse is low. Treatment of childhood leukemia is currently achieved by using %22protocol treatment%22 that usually lasts at least 1.5 years and has elaborate sequence of therapeutical modalities that are combined in well controlled international studies. The Czech Republic is a member of the BFM-group (whose members also include Germany-Austria-Italy). This group develops leukemia treatment protocols that are the most successful in current pediatric hematology. Furthermore, several compounds were implemented in the recent years that act as %22targeted therapeutics%22 and target specifically the leukemia associated molecular abnormalities. The best example is imatinib mesylate (glivec) used for leukemias bearing the BCR/ABL translocation and many others small inhibitors. Our current task is to find appropriate role of these new compound in the treatment protocols and to find correlates of good response to these compounds. Large scale protein analysis, such as the antibody array technology is instrumental in finding the profile of good response of the leukemia cells. (en)
|
| Title
| - EEA/Norwegian Financial Mechanisms and Ministry of education, Youth and Sports of Czech republic (en)
- EEA/Norwegian Financial Mechanisms and Ministry of education, Youth and Sports of Czech republic
|
| skos:notation
| |
| http://linked.open...avai/cep/aktivita
| |
| http://linked.open...kovaStatniPodpora
| |
| http://linked.open...ep/celkoveNaklady
| |
| http://linked.open...datumDodatniDoRIV
| |
| http://linked.open...i/cep/druhSouteze
| |
| http://linked.open...ep/duvernostUdaju
| |
| http://linked.open.../cep/fazeProjektu
| |
| http://linked.open...ai/cep/hlavniObor
| |
| http://linked.open...hodnoceniProjektu
| |
| http://linked.open...vai/cep/kategorie
| |
| http://linked.open.../cep/klicovaSlova
| - leukemia, protein arrays (en)
|
| http://linked.open...ep/partnetrHlavni
| |
| http://linked.open...inujicichPrijemcu
| |
| http://linked.open...cep/pocetPrijemcu
| |
| http://linked.open...ocetSpoluPrijemcu
| |
| http://linked.open.../pocetVysledkuRIV
| |
| http://linked.open...enychVysledkuVRIV
| |
| http://linked.open...lneniVMinulemRoce
| |
| http://linked.open.../prideleniPodpory
| |
| http://linked.open...iciPoslednihoRoku
| |
| http://linked.open...atUdajeProjZameru
| |
| http://linked.open...usZobrazovaneFaze
| |
| http://linked.open...ai/cep/typPojektu
| |
| http://linked.open...ep/ukonceniReseni
| |
| http://linked.open.../cep/vedlejsiObor
| |
| http://linked.open...ep/zahajeniReseni
| |
| http://linked.open...jektu+dodavatelem
| - Hodnocení výsledků řešení ministerstvo neprovádí, neboť podmínkou podpory je, že uchazeč byl vybrán mezinárodním poskytovatelem v souladu s pravidly příslušného programu. Projekt je hodnocen až po jeho schválení mezinárodním poskytovatelem. (cs)
- Following the condition that the candidate of financial contribution was evaluated and afterwards selected by international provider in accordance with the rules of the program the Ministry of Education, Youth ans Sports does not realize the evaluation of project results. The project is evaluated only after its approval by an international provider (en)
|
| http://linked.open...tniCyklusProjektu
| |
| http://linked.open.../cep/klicoveSlovo
| |
| is http://linked.open...vavai/riv/projekt
of | |
| is http://linked.open...vavai/cep/projekt
of | |
![[RDF Data]](/fct/images/sw-rdf-blue.png)
![[cxml]](/fct/images/cxml_doc.png)
![[csv]](/fct/images/csv_doc.png)
![[text]](/fct/images/ntriples_doc.png)
![[turtle]](/fct/images/n3turtle_doc.png)
![[ld+json]](/fct/images/jsonld_doc.png)
![[rdf+json]](/fct/images/json_doc.png)
![[rdf+xml]](/fct/images/xml_doc.png)
![[atom+xml]](/fct/images/atom_doc.png)
![[html]](/fct/images/html_doc.png)